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Edited by Ulf-Ingo Flu¨ggeAbstract RPLKPW is a potent anti-hypertensive peptide de-
signed according to the structure of ovokinin(2–7) (RADHPF).
In this study, we generated transgenic rice plants that accumu-
late the RPLKPW peptide as a fusion protein with the rice
storage protein glutelin. The engineered peptide is expressed
under the control of endosperm-speciﬁc glutelin promoters
and speciﬁcally accumulates in seeds. Oral administration of
either the RPLKPW-glutelin fraction or transgenic rice seeds
to spontaneously hypertensive rats (SHRs) signiﬁcantly reduced
systolic blood pressures. These results suggest the possible
application of transgenic rice seed as a nutraceutical delivery
system and speciﬁcally for administration of active peptides
in hypertension.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hypertension is a disease that involves complex interactions
between genetic, dietary and environmental factors [1–3].
Approximately 1 billion people worldwide suﬀer with this dis-
ease. When hypertension is undiagnosed or uncontrolled, it
places patients at risk for other cardiovascular diseases, con-
tributing to an increase in mortality and morbidity. Hyperten-
sion is closely associated with diet, but a diet rich in foods with
anti-hypertensive activity can potentially prevent or reduce dis-
ease severity as a supplement to drug therapy.
RPLKPW [4] is a potent anti-hypertensive peptide that was
designed based on the structure of ovokinin(2–7) (RADHPF)
[5], a vasorelaxing peptide derived from ovalbumin. Oral
administration of RPLKPW at a dose of 0.1 mg/kg has been
shown to lower the systolic blood pressure of spontaneouslyq The GenBank/EMBO/DDBJ accession numbers of the nucleic acid
sequences used in this study are as follows: Glutelin A2: X05664;
Glutelin B1: X54314; Glutelin C: AB016501; Glutelin B1 promoter:
AY427569; Glutelin B2 promoter: AY427570; Glutelin B4 promoter:
AY427571; Hygromycin phosphotransferase: AY373338.
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doi:10.1016/j.febslet.2006.04.092hypertensive rats (SHRs). When RPLKPW sequences were
introduced into three sites of the a
0
subunit of soybean b-con-
glycinin by base substitution mutation, the modiﬁed protein
lowered the systolic blood pressure of SHRs at a dose of
10 mg/kg [6]. Furthermore, for improvement of RPLKPW
peptide release from fusion protein, modiﬁcation of the pep-
tide was attempted by addition of arginine (R) and glutamine
(Q) residues to the amino and carboxy termini respectively.
When these RRPLKPWQ sequences were introduced into
the corresponding regions of the subunit, the modiﬁed protein
reduced blood pressure at a dose of 2.5 mg/kg [7]. The result
demonstrates that the addition of the R–Q spacer facilitates
RPLKPW release in vivo by gastrointestinal proteases. While
the systolic blood pressure in normotensive rats was not af-
fected even by a high dose of RPLKPW peptide [5], which
indicates that it may be an ideal functional peptide with anti-
hypertensive activity, and is a candidate for further hyperten-
sive remediation study. Therefore, it is conceivable that a novel
oral deliverable food, or ‘nutraceutical’ can be developed that
could be used to control or prevent clinical hypertension.
Plants have many advantages as bioreactors for the produc-
tion of pharmaceuticals, vaccines and antibodies [8,9]. Com-
pared to current competing technologies such as microbial
and mammalian cell culture systems, plants provide a means
of low cost production with almost no risk of contamination
by animal pathogens. In addition, pharmaceutical products ex-
pressed in cereal crop seeds or tubers are highly stable and can
be stored for long periods at room temperature with no loss of
activity [10]. Functional peptides or vaccines accumulated in
seeds do not require any processing or puriﬁcation, thus allow-
ing direct oral delivery [11]. Taken together, plants provide an
economic, safe and stable production system for recombinant
products.
In this study, we developed transgenic rice plants that accu-
mulate anti-hypertensive peptides (RRPLKPWQ) in seeds. To
increase accumulation, the peptide was expressed as fusion
proteins with the major rice glutelin storage proteins [12–14].
Under the control of strong rice endosperm-speciﬁc promoters
[15], the fusion proteins were accumulated to around 10% of
total seed protein. Oral administration of isolated fusion pro-
tein or transgenic rice seeds to SHRs signiﬁcantly reduces sys-
tolic blood pressure. This is the ﬁrst study that indicates the
potential of an active and eﬀective role for rice based anti-
hypertensive bioactive peptides as a dietary supplement for
hypertension patients.blished by Elsevier B.V. All rights reserved.
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2.1. Plasmid construction and rice transformation
For the construction of pGluB1-HRP (glutelin B1 containing the
Hypertension Reducing Peptide), 15 and 13 amino acid residues of the
variable regions of the acidic subunit (between positions 210–224 and
284–296 from the precursor initiation codon) of glutelin B1 (GluB1)
[12] were substituted with a RRPLKPWQ dimer peptide (RRPLKPW-
QRRPLKPWQ), and the C terminal variable region of the basic subunit
(residues 492–499) was replaced with the RRPLKPWQ sequence
(Fig. 1). Introduction of peptides into the variable regions was accom-
plished using a method with two or three stages of PCR ampliﬁcation
as previously described [16]. The modiﬁed GluB-1 cDNA, containing a
total of ﬁve copies of the RRPLKPWQ peptide, was linked to the
2.3 kb glutelin GluB-1 promoter [15] and then inserted into the binary
vector pGTV-35S-HPT [17], resulting in pGluB1-HRP. The glutelin
A2 and glutelin C HRP fusion (pGluA2-HRP/GluC-HRP) was con-
structed by substituting the RRPLKPWQ dimer peptide for the 15
and 14 amino acid residues in the variable regions of the acidic subunit
between positions 211–225 and 270–283 of GluA2 [13], and for the 14
and 15 amino acids between positions 214–227 and 303–317 of GluC
[14]. GluA2-HRP and GluC-HRP thus each contained four copies of
the RRPLKPWQ peptide, were fused to the 2.4 kb glutelin B-2 (GluB-
2) and 1.4 kb glutelinB-4 (GluB-4) promoters, respectively [15], andwere
inserted in tandem into the binary vector pGTV-35S-HPT (Fig. 1). The
ﬁdelity of all DNA constructs was conﬁrmed by sequencing.
Glu-HRP constructs were introduced into the rice genome (Oryza
sativa cv. Kita-ake) by Agrobaterium tumefaciens-mediated transfor-
mation and transgenic plants were selected by resistant to hygromycin
as described by Goto et al. [18]. The transgenic plants were grown in a
controlled greenhouse (28 C, 12 h light/dark cycle) until harvesting.
2.2. Southern blot analysis
Genomic DNA was prepared from young leaves with a CTAB meth-
od [19]. Ten micrograms of DNA were digested with XbaI or SacI,
fractionated by electrophoresis on 0.8% agarose gel and transferred
onto a nylon membrane (HybondN+, Amersham Biosciences). South-
ern blot analysis was carried out by using standard method [17].
Hybridization was performed at 65 C by using a full-length hpt probe
labeled by random priming reaction (megaprime DNA labeling sys-
tem, Amersham Biosciences) with 32P.Fig. 1. Construction of expression plasmids for rice transformation. (A)
hygromycin phosphotransferase gene; pAg7, 3 0 terminal region of agropine sy
coding region; GluB-1, rice glutelin B1 coding region; GluC, rice glutelin C co
1 P, GluB-2 P and GluB-4 P represent 2.3 kb glutelin B1, 2.4 kb B2 and 1.4 k
B1 and 0.7 kb B4 3 0 terminal regions, respectively; blank triangle, RRPLK
glutelin B1; solid triangles, dimer peptide RRPLKPWQRRPLKPWQ substit
amino acid sequence at variable regions of glutelins. The amino acid residue
subunit are double underlined. Numbers indicate the position of the amino
precursors; Asterisk stands for stop codon.2.3. Antibody preparation
The NH2-GCRRPLKPWQRRPLKPW-OH peptide was synthe-
sized by BIO-Synthesis incorporated (USA) and used to raise anti-
RPLKPW antibody in a rabbit (Qiagen, Tokyo).2.4. Detection of GluB1-HRP and GluA2-HRP/GluC-HRP fusion
proteins
Rice seeds were ground to a ﬁne powder with a Multibeads shocker
(Yasui Kikai, Osaka, Japan), and total proteins were extracted with a
Urea–SDS buﬀer (50 mM Tris–Cl (pH 6.8), 8 M urea, 4% SDS, 5%
mercaptoethanol, 20% glycerol) as described previously [20]. After sep-
aration by 12% SDS–PAGE and transfer to PVDF membranes (Milli-
pore), fusion proteins were detected with anti-RPLKPW antibody
(1:10000 dilution) followed by a goat anti-rabbit IgG secondary anti-
body conjugated to horseradish peroxidase (1:5000 dilution) (Promega).
Fusion protein accumulation levels were determined with quantita-
tive immuno-dot-blots with an anti-RPLKPW antibody [20] and
Glu-HRP fusion protein produced in an E. coli culture was used as
standard.
2.5. Extraction and puriﬁcation of total glutelins
Extraction and puriﬁcation of total glutelins were performed accord-
ing to Tada et al. [20]. Brieﬂy, glutelins were extracted with 1% (v/v)
lactic acid from 12 g seed powders after stepwise removal of albumins
and globulins with 12 ml saline buﬀer (10 mM Tris–HCl pH 7.5, 0.5 M
NaCl) followed by removal of prolamins with 12 ml 60% (v/v) n-pro-
panol solution. Each extraction step was accomplished by resuspend-
ing seed powder in the solution and sonicating on ice for several
minutes. After centrifugation (10000 rpm, 10 min) the residues were
extracted twice more with the same solution. The concentration of
combined glutelin fractions was determined by Bradford method with
a Bio-Rad Protein Assay kit 1 (Catalog No. 500-0001, Bio-Rad).
2.6. Animals
Male spontaneous hypertensive-Izumo rats (SHR) were purchased
from SLC, Shizuoka, Japan. Each group of six rats was fed with SP
chow (Funakoshi Farm) and water ad libitum, and was housed in a
temperature-controlled room on a 12 h light/dark cycle. This study
was performed in accordance with Kyoto University guidelines for
the care and use of laboratory animals.Diagram of two expression plasmids used for transformation. hpt,
nthase gene; RB, right border; LB, left border; GluA-2, rice glutelin A2
ding region; Nos T, 3 0 terminal region of nopaline synthase gene; GluB-
b B4 promoters, while GluB-1 T and GluB-4 T indicate 0.65 kb glutelin
PWQ peptide substitution site at variable region of basic subunit of
ution sites at variable regions of acidic subunits of glutelins. (B) Partial
s substituted in acidic subunits are underlined, while the ones in basic
acid residues starting from the translation initiation codon of glutelin
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Glutelin fractions isolated from non-transgenic and transgenic rice
seeds were dissolved in 1% lactic acid and administrated orally to
SHRs at 18–22 weeks after birth using a metal sonde in a volume of
1.6–1.9 ml/rat. Pulverized seeds from either non-transgenic or trans-
genic rice were homogenized in water with a Polytron homogenizer
and orally administered in a volume of 3.0 ml/rat. Systolic blood pres-
sured was measured by the indirect tail cuﬀ method using an MK-2000
sphygmomanometer (Muromachi Kikai). Blood pressure was mea-
sured every 2 h following oral administration.2.8. Data analysis
Statistical signiﬁcance was determined using Student’s t-test, with
P < 0.05 as the threshold for signiﬁcance. Results of blood pressure
measurements are expressed as means ± S.E.M.3. Results
3.1. Characterization of transgenic rice plants
Thirty individual transgenic rice plants were generated for
each pGluB1-HRP and GluA2-HRP/GluC-HRP construct
and fusion protein expression levels were determined by quan-
titative immuno-dot blot using the anti-RPLKPW peptide
antibody (Fig. 2). The accumulation levels of GluB1-HRP ran-
ged from 0.2% to 9.6% (Fig. 2A), while GluA2-HRP/GluC-
HRP from 1.9% to 13.7% (Fig. 2B) of total seed protein.
The highest expression lines were selected from pGluB1-HRP
(No. 6) and pGluA2-HRP/GluC-HRP (No. 30) constructs.
Southern blot analysis was performed using genomic DNA di-
gested with SacI (line 6) and XbaI (line 30) to determine the
copy number of transgenes. As shown in Fig. 3A, at least three
copies of the transgene were estimated to be present in each
transgenic line.
Western blot analysis was used to examine the expression of
the glutelin-HRP fusion proteins in transgenic rice grain using
anti-RPLKPW antibody. Rice glutelin is synthesized as a pre-
cursor form and then post-translationally processed into ma-
ture acidic and basic subunits, thus it was necessary to
examine whether the glutelin-HRP fusion proteins were pro-
cessed after insertion of the exogenous peptide sequences. AsFig. 2. Dot blot analysis of Glu-HRP fusion proteins in transgenic rice seeds
GluA2-HRP/GluC-HRP (B) were spotted onto a nitrocellulose membrane. T
sequentially diluted standard Glu-HRP proteins (between 2.5 and 100 ng) pu
corresponding constructs and NT stands for non-transgenic rice cv. Kita-akshown in Fig. 3B, there are three bands representing the pre-
cursor, acidic and basic subunits with molecular masses of
55, 33 and 22 kDa, respectively, in case of the pGluB1-HRP
construct (Fig. 3B, lanes 2 and 3). On the other hand, four
bands were detected for the pGluA2-HRP/GluC-HRP con-
struct, which represented the GluC-HRP (56 kDa) and
GluA2-HRP (55 kDa) precursors, GluC-HRP (34 kDa) and
GluA2-HRP (33 kDa) acidic subunits, respectively (Fig. 3B,
lanes 4 and 5). Since the molecular masses of the acidic sub-
units of GluC-HRP and GluA2-HRP were very close, it was
diﬃcult to separate them by SDS–PAGE. After the same mem-
brane was re-blotted with anti-GluC antibody and the electro-
phoretic mobility was compared carefully, it was apparent that
the upper band was derived from GluC-HRP, and the lower
one was from GluA2-HRP (Data not shown). These results
indicate that all three of glutelin-HRP fusion proteins were
processed normally in rice endosperm tissues.
3.2. Anti-hypertensive activity of glutelin-HRP after oral
administration in SHRs
To eliminate the possibility of confounding variables due to
the presence of starch, albumin, globulin and prolamin in rice
seeds, and to evaluate the anti-hypertension activity of themod-
iﬁed glutelin-containing RRPLKPWQ peptides, we isolated a
crude glutelin fraction that contained both endogenous glutelin
and the GluB1-HRP glutelin fusion protein from mature seeds.
As shown in Fig. 4A, the glutelin fraction signiﬁcantly lowered
systolic blood pressure at the maximum of 28 ± 7 mmHg in
SHRs at 4 h after oral administration at dose of 30 mg of total
glutelin protein/kg rat weight, which is equivalent to 2.2 mg of
GluB1-HRP fusion protein/kg or 140 lg of RPLKPW peptide/
kg. A half-dose (equivalent to 70 lg the peptide) gave a maxi-
mum decrease at 2 h after oral administration with a propor-
tional reduction (12 ± 2.2 mmHg) (Fig. 4B). This result may
suggest a dose-dependent relationship to anti-hypertensive
activity. It is notable that the glutelin fraction isolated from
kita-ake seeds as a control showed no eﬀect at any time or dose.
To further examine whether transgenic rice seeds possess
anti-hypertensive function without any puriﬁcation steps, 1 g. Extracts (1 lg of proteins) of mature seeds from GluB1-HRP (A) and
he fusion protein level in each dot was determined by comparing with
riﬁed from E. coli cells. The number below each dot indicates lines of
e.
Fig. 3. Analysis of transgenic rice expressing the RPLKPW peptide. (A) Southern blot analysis. Genomic DNA isolated from young leaves was
digested with SacI (line 6 of GluB1-HRP) and XbaI (line 30 of GluA2-HRP/GluC-HRP) and hybridized with a 32P-labelled hpt probe. Non-
transgenic rice cultivar Kita-ake served as control. (B) Western blot analysis. Total proteins extracted from two independent homozygous seeds of
GluB1-HRP (line 6) (lanes 2 and 3) and GluA2-HRP/GluC-HRP (line 30) (lanes 4 and 5), and from one seed of non-transgenic cv. Kita-ake (lane 1)
were separated by 12% SDS–PAGE and immuno-detected with anti-RPLKPW antibody.
Fig. 4. Anti-hypertensive activities of GluB1-HRP fusion protein and transgenic rice seeds of GluA2-HRP/GluC-HRP. (A) Oral administration of
30 mg/kg (equivalent to 140 lg of RPLKPW peptide/kg), and (B) 15 mg/kg (equivalent to 70 lg of the peptide/kg) of a crude glutelin fraction
(containing endogeous glutelin and GluB1-HRP fusion protein); (C) oral administration of 1 g/kg (equivalent to 470 lg of peptide/kg) of unpolished
pulverized GluA2-HRP/GluC-HRP rice seeds. Solid square, GluB1-HRP glutelin fraction or GluA2-HRP/GluC-HRP seeds; Blank square, glutelin
fraction or seeds from Kita-ake. *P < 0.05, **P < 0.01, ***P < 0.001.
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SHRs, their systolic blood pressure was somewhat reduced to
certain level but with no statistical signiﬁcance (data not
shown). Therefore, pulverized GluA2-HRP/GluC-HRP seeds
with higher amounts of RRPLKPWQpeptide were used for test
instead. As shown in Fig. 4C, the systolic blood pressure of
SHRs was reduced an average of 15.6 ± 4.8 mmHg at 2 h
after oral administration at a dose of 1 g grain/kg, which corre-
sponds to 9.5 mg of the fusion protein/kg or 470 lg of
RPLKPW peptide/kg.4. Discussion
Hypertension is a worldwide epidemic and is one of the most
important risk factors leading to other health problems. Apart
from medical treatment, lifestyle changes and dietary manage-
ment may be eﬀective in reducing blood pressure in hyperten-
sion patients or prehypertension candidates. In this study, a
new approach for prevention of hypertension was attemptedby taking advantage of transgenic rice plants that accumulate
active anti-hypertensive peptides.
It has been reported that the production of small peptides of
less than 30 amino acids is diﬃcult in plants, possibly due to
degradation by endogenous proteases or silencing by suppres-
sion or co-suppression mechanisms [17]. These problems have
been resolved by expressing the peptide as a part of common
seed storage proteins, inserted into the variable regions
[16,21,22]. In this study, we enhanced the accumulation levels
by introduction of optimized RRPLKPWQ sequence into the
variable regions of glutelins and expressed the fusion proteins
under the control of three strong rice storage protein glutelin
promoters [15]. The fusion proteins accounted for around
10% of the total seed protein (Fig. 2). It is notable that the fu-
sion proteins processed properly into a mature form with
acidic and basic subunits (Fig. 3B). These data suggest that
replacement of sequences in the variable region of glutelin does
not aﬀect the sorting of glutelin-HRP fusion proteins into pro-
tein storage vacuoles (PBII), since only proteins that are cor-
rectly localized can be processed and folded to the stable and
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bean seed storage protein arcelin 5-1 and b-phaseolin promot-
ers enhanced the accumulation level of functional murine scFv
to 12.5% and 36.5% of total soluble protein in transgenic dicot-
yledonous seeds, thus demonstrating that these seed storage
promoters provide a promising means for large-scale produc-
tion of economically useful recombinant products.
It has been reported that the eﬀective dose required for
reduction of blood pressure of SHRs is 100 lg/kg [4]. In this
study, administration of 2.2 mg and 1.1 mg of GluB1-HRP fu-
sion protein (equivalent to 140 lg and 70 lg of the RPLKPW
peptide, respectively) to SHRs lowered the systolic blood pres-
sure signiﬁcantly (Figs. 4A and B). The results indicated that
the RPLKPW sequence was released from fusion proteins
properly in small intestine by ﬂanking the RPLKPW peptide
sequences with R and Q residues. When GluB1-HRP (contain-
ing ﬁve copies of RPLKPW sequences) and GluA2-HRP/
GluC-HRP (having eight copies of RPLKPW sequences) seeds
were administrated to SHRs at a dose of 1 g grain, only the lat-
ter reduced the systolic blood pressure signiﬁcantly. The results
suggest that improvement of anti-hypertensive activity of
transgenic seeds can be achieved by increasing the accumula-
tion levels as well as copies of inserted RPLKPW peptide in fu-
sion proteins. The reason for much higher dose requirement
(equivalent to 470 lg/kg of the RPLKPW peptide) in case of
seeds is unclear (Fig. 4C), one possible explanation is that
seeds may not be easily digested and assimilated in an un-
cooked form in the digestive organs after oral administration.
The transgenic rice generated in this study is functional for
reducing blood pressure of SHRs after oral administration.
Our results showed that both the glutelin fraction containing
glutelin-HRP fusion proteins and the unpolished transgenic
rice seeds eﬀectively reduced systolic blood pressure (Fig. 4).
At present, we are crossing high expression transgenic rice lines
to increase the accumulation of glutelin-HRP fusion proteins.
Primary results indicate that hybrid lines have about 50% high-
er levels than their parental lines. Alternatively, an attempt to
accumulate multiple RRPLKPWQ peptides directly in rice
seed is in progress. Our purpose in this study is to produce hy-
per-expression rice plants that can potentially serve as an eﬀec-
tive food supplement for hypertension patients.
Plant-derived biopharmaceuticals should meet the same
standards of safety and performance as other production sys-
tems. However, one of the public concerns is the presence of
antibiotic resistance genes or their products in edible parts of
genetically modiﬁed crops. It can be overcome by using an
antibiotic-free selection system like a MAT-vector system
[24]. The other major concern is the possible contamination
of non-transgenic crop seeds by out-crossing with transgenic
pollens in the ﬁeld or in the process of transportation. There-
fore, methods for transgene containment are required to be
developed. Although further investigation with regard to the
safety evaluation such as allergenicity and chronic toxicity re-
mained to be performed, incorporation of the bioactive pep-
tide into rice storage proteins could assume a greater role for
dietetics of hypertension in the near future.
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